Neuraxis, INC (NRXS) stock
NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$4.87+0.26 (+5.64%)
Close on Nov 18, 2026Market cap $61.16MP/E –Yield –
Neuraxis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Neuraxis's operating income for the twelve months ending Jun 30, 2026 was -$7.68M. For fiscal 2025 it was -$7.83M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.83M | – |
| FY2024 | Dec 31, 2024 | -$7.16M | – |
| FY2023 | Dec 31, 2023 | -$6.66M | – |
| FY2022 | Dec 31, 2022 | -$3.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.30M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.21M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$896.27K | – |
| Q4 FY2022 | Dec 31, 2022 | -$986.23K | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$669.58K | – |
See a number that looks wrong?